Core Insights - BioHarvest Sciences has achieved a significant milestone by producing plant-based exosomes at scale using its proprietary Botanical Synthesis technology, which opens new revenue streams and CDMO opportunities [1][3][6] Company Developments - The company’s bioreactors are designed to optimize the production of high-yield, high-value exosomes, setting it apart from conventional systems [3] - BioHarvest's exosomes contain viniferin, a polyphenol known for its anti-aging and antioxidant benefits, providing a more effective delivery method compared to traditional formulations [4][5] - The CEO of BioHarvest anticipates launching a differentiated skincare product utilizing these exosomes within 18 to 24 months [5] Market Potential - The global exosome market is projected to grow from $0.7 billion in 2025 to $2.2 billion by 2030, indicating a strong demand for plant-based exosomes as a safer alternative to synthetic options [6] - This development represents a new monetization path for the company, enhancing the value derived from its core technology [6]